pitch its story to Wall Street. It settled on Mr. Hugin, a managing director at J.P. Morgan.","type":"text"}, {"bannerType"™: "any", "identifier":" anf-banner advertisement-— 5","layout"™:"ComponentLayout-— 4","role":"banner advertisement", "type":"banner advertisement"}, {"additions": [{"URL™:"h ttps://bobhugin.com/about/", "range": {"length":19, "start ":176}, "type"™:"Link"}, {"URL":"ht tps://www.sec.gov/Archives/edgar/data/816284/000100515000000449/0001005150-00- 000449.txt", "range": {"length":21,"start":223},"type™:"link"}],"identifier":" anf-body- 27","inlineTextStyles": [{"range"™:{"length":461,"start":0},"textStyle":"_ anf-ts- i"}, {"range"™:{"length":461,"start":0},"textStyle":" anf-ts-1"}],"layout":"default- body", "role": "body", "text": "At the time, the companyde€™s financial situation was perilous. Celgene had 200 employees and was getting by on less than six weeks of cash when Mr. Hugin joined, according to his campaign biography. A year later, the company warned investors that, A€eduring the next several years, we will be very dependent on the commercial success of Thalomid,d4€ while also acknowledging that the market for the only disease for which the drug was approved was a€erelatively small.a€","type":"text"™}, {"identifier":" anf-heading4- 2","layout":"heading4", "role": "heading4", "text":"Seeking a windfall by exploiting drug safety rules", "type":"text"}, {"identifier":" anf-body- 28","inlineTextStyles": [{"range"™:{"length":387,"start":0},"textStyle":"_ anf-ts- i"}, {"range™: {"length":387,"start":0},"textStyle":" anf-ts-1"}],"layout":"default- body", "role":"body", "text":"Drug companies are forbidden from promoting a drug for any unapproved uses, but doctors have broad discretion to prescribe a product for a range of diseases. Celgene appeared to exploit this distinction almost as soon as Thalomid arrived on the market, according to company filings, public statements and internal documents included in the whistle-blower lawsuit Celgene set